May 17, 2020

New Health Lottery to earn £50m for healthcare services

Health Lottery
National Lottery
Richard Desmond
Northern
Admin
3 min
Tickets for the Health Lottery go on sale this week
Richard Desmond, the owner of the media company Northern & Shell, will be launching a new UK TV lottery show later this week. The Health Lottery wi...

Richard Desmond, the owner of the media company Northern & Shell, will be launching a new UK TV lottery show later this week.

The Health Lottery will rival Camelot’s National Lottery that is currently run in the UK and will donate money from the sale of tickets to a number of charitable healthcare foundations.

It is hoped the Health Lottery will raise £50 million a year for services outside of the NHS, in addition to increasing Northern & Shell’s charitable donations and being a profitable venture for the company.

To read the latest edition of Healthcare Global, click here

The beneficiaries of the new lottery will be decided by local health interest groups and an independent charitable trust will distribute the cash.

It is expected the money will go to a wide range of services, from supporting young carers to training specialist nurses.

However, the new scheme has been criticised because it will donate less money to good causes than the existing National Lottery.

While tickets for the Health Lottery will cost £1 – the same as tickets for the standard National Lottery draw – only 20 pence will go to health causes, compared to Camelot’s donation of 28 pence from each pound.

Sir Stephen Bubb, from the Association of Chief Executives of Voluntary Organisations, voiced his opinions on the new gamble to The Times newspaper.

He said it was a “pretty disgraceful development” before adding: “The Government needs to look at lottery regulation to ensure it’s made transparent to people who play that this new lottery is giving a lot less per £1 to good causes.”

However, the move was defended by Desmond, who said he truly believes donations from the Health Lottery will “touch every part of England, Scotland and Wales.”

Meanwhile, Martin Hall, the Chief Executive of the new game, said every community in Britain would experience its benefits.

When he first purchased the Health Lottery, Desmond said: “This is a great way of being able to get across more than £50m a year to change people's lives. That's why we got involved. It's a very exciting project.”

Tickets for the Health Lottery will be available to buy from 29 September and over 40,000 retailers have signed up to be vendors.

The top prize will be £100,000 and will be awarded if participants match five numbers on their ticket with the results of the draw.

The draw will take place on Saturday nights and will be shown during adverts on two television channels in the UK – ITV and Channel 5.

Our magazine is now available on the iPad. Click here to download it.

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article